STAT Plus: Aimmune Therapeutics, maker of peanut allergy treatment, will be acquired by Nestle
PATRICK SISON/AP
Aimmune believed Palforzia could deliver annual sales exceeding $1 billion, but the coronavirus shutdowns severely impacted its launch.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario